AAV2.7m8 vector system (inner ear&retina-validated AAV expression and packaging plasmids)
Capsid mutant-AAV serotype 2 variant (AAV2.7m8) system-Introduction
GeneMedi's AAV2.7m8 Vector System (AAV serotype 2.7m8 helper-free packaging plasmids system) is including AAV2.7m8 Rep-Cap plamid (AAV2.7m8-RC plasmid), AAV helper plasmid and AAV expression vectors (overexpression or shRNA).
You can choose your suiltable AAV expression vector plasmids from GeneMedi's AAV expression vector core. The AAV expression vector plasmids were constructed with differernt expression cassettes,containing kinds of verified protomters and reporters including GFP, zsgreen, RFP, mcherry and luciferase. The GeneMedi's AAV expression vectors have been proved very suitalble for unique gene overexpression or shRNA-mediated knock-down (also called RNAi (RNA interference ). You can also achieve gene knock-out(KO) or gene editing using our Crispr-cas9-gRNA AAV expression vector.
AAV2.7m8 Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV2 7m8 capsid-engineered protein.
The tissue tropism of AAV2.7m8 vector has been validated in inner ear. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.AAV2-7m8 also shows the potential tropism in retina in vivo and retinal cell in vitro.
|Product Name||Contents||Price(In USD)||Qty||Sum(In USD)|
|AAV2 variant (AAV2.7m8) vector system||1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. AAV CMV Expression Vector, 5ug||1440|
AAV2 capsid variant (AAV2.7m8) tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV2.7m8 vector has been validated in inner ear. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.
Virus and titer: AAV2 variant (AAV2.7m8) vector system, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: retina Gene delivery method: subretinal cavity injection, 3μl Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy
Other AAV vector system